Navigation Links
Bone marrow mononuclear stem cells show no new gains in heart function says TIME study
Date:11/18/2013

MINNEAPOLIS, MN November 18, 2013 New data reported by the Cardiovascular Cell Therapy Research Network (CCTRN) at the 2013 Scientific Sessions of the American Heart Association in Dallas showed that the use of bone marrow mononuclear stem cells (BMCs) did not improve heart function significantly more at one year than at six months. While there was measurable decrease in the size of scar tissue at six and 12 months, stem cells administered as a part of the TIME (Transplantation In Myocardial Infarction Evaluation) study did not improve overall heart functionality. The results were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation on Monday, Nov. 18.

"While there are no safety issues with BMC's, the resulting reduction in scar tissue (infarct size) at six months and at one year and the small improvement in left-ventricular function was no different than a placebo, suggesting that these types of stem cells would appear to be of low therapeutic efficacy, " stated Jay Traverse, MD, of the Minneapolis Heart Institute Foundation. "At this early stage of stem cell therapy research investigating viable post-heart attack strategies, our study and others suggest that we should look at other, more potent stem cells as a means to improving functionality following a heart attack." Traverse noted that this is one of the largest serial cardiac MRI studies examining the changes in left-ventricular function following a heart attack.

In this analysis, the administration of BMC's following moderate to large anterior STelevated myocardial infarction (STEMIs) was not associated with improved recovery of global and regional left ventricular (LV) function at one year compared to placebo. Levels of left ventricular ejection fraction (LVEF) increased from baseline to six months but did not improve further between six months and one year in either the BMC or the placebo group. On average, infarct size decreased in the BMC and placebo groups
'/>"/>

Contact: Steve Goodyear
sgoodyear@mhif.org
612-863-1654
Minneapolis Heart Institute Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Newly identified bone marrow stem cells reveal markers for ALS
2. Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use
3. Researchers discover brain cancer treatment using genetic material from bone marrow cells
4. Scientists find bone-marrow environment that helps produce infection-fighting T and B cells
5. Bone marrow cells used in bladder regeneration
6. Bone marrow stem cells do not improve short-term recovery after heart attack
7. Study results: Adult stem cells from bone marrow
8. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
9. Cell therapy using patients own bone marrow may present option for heart disease
10. Bone marrow transplant arrests symptoms in model of Rett syndrome
11. Salk scientists for the first time generate mini-kidney structures from human stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
(Date:10/22/2014)... 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... steps for its Oral Amphotericin B program.  The ... in vitro work involving samples from HIV/AIDS ... to complete pre clinical studies and regulatory filings ... clinical trial, utilizing approximately $700,000 of funding and ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Company Cites Important Progress With Needle-free Vaccine Technology and ... Bird Flu ... March 31, 2008, IRVING, Texas, March 31 Carrington,Laboratories, Inc. ... net loss of $9.8 million, or ($0.90) per basic and,diluted share, ...
... Inc. (NYSE: CRY ),(the "Company"), a biomaterials, ... entered into a credit facility with GE Healthcare,Financial ... in revolving,credit for working capital, acquisitions and other ... at which time the outstanding,principal balance will be ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 2CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 3